Selecting the Best Combined Biological Therapy for Refractory Inflammatory Bowel Disease Patients

Autores de I3PT

• Eduard Brunet Mas

  Autor

• 

  Xavier Calvet Calvo

  Autor

Grupos de Investigación

• Malatia inflamatòria intestinal hepàtica i Helicobacter pylori

  

  Investigador

  Xavier Calvet Calvo

Abstract

Current medical treatment for inflammatory bowel disease (IBD) does not achieve 100% response rates, and a subset of refractory and severely ill patients have persistent active disease after being treated with all possible drug alternatives. The combination of two biological therapies (CoT) seems a reasonable alternative, and has been increasingly tested in very difficult cases. The present review suggests that CoT seems to be safe and effective for refractory and severely ill IBD patients. Ustekinumab plus vedolizumab and vedolizumab plus anti-TNF were the most used CoTs for Crohn's disease. For ulcerative colitis, the most used CoTs were vedolizumab plus anti-TNF and vedolizumab plus tofacitinib. The aforesaid CoTs have shown good efficacy and few adverse events have been reported.

Keywords

• inflammatory bowel diseases; biologic treatment; combination; Crohn's disease; ulcerative colitis